Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      
           
This page is updated frequently with new Vaccine-related patent applications. Subscribe to the Vaccine RSS feed to automatically get the update: related Vaccine RSS feeds. RSS updates for this page: Vaccine RSS RSS



Date/App# patent app List of recent Vaccine-related patents
07/23/15
20150203830 
 Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes patent thumbnailCompositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes
The present invention provides peptides and proteins for use in second generation hiv vaccines and as diagnostic tools in the treatment and control of hiv infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an hla epitope-enhanced vaccine.
The Government Of The United States Of America As Represented By The Secretary Of The Departmen Of H


07/23/15
20150203547 
 Use of p47 from plasmodium falciparum (pfs47) or plasmodium vivax (pvs47) as a vaccine or drug screening targets for the inhibition of human malaria transmission patent thumbnailUse of p47 from plasmodium falciparum (pfs47) or plasmodium vivax (pvs47) as a vaccine or drug screening targets for the inhibition of human malaria transmission
The inventors have identified pfs47, a gene from the malaria parasite p. Falciparum, as a key factor for survival of these parasites in the mosquito anopheles gambiae.
The United States Of America, As Represented By The Secretary, Dhhs


07/23/15
20150203523 
 Synthesis of diverse glycosylphosphatidylinositol glycans from toxoplasma gondii and their application as vaccines and diagnostics patent thumbnailSynthesis of diverse glycosylphosphatidylinositol glycans from toxoplasma gondii and their application as vaccines and diagnostics
The present invention relates to the synthesis of gpi-related surface antigens of the parasite toxoplasma gondii (t. Gondii) and the resulting products obtained.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.


07/23/15
20150202281 
 Molecular antigen array patent thumbnailMolecular antigen array
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array.
Novartis Pharma Ag


07/23/15
20150202279 
 Antigens and antigen combinations patent thumbnailAntigens and antigen combinations
Nthi protein antigens have been identified and found to be conserved across several haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity.
Novartis Ag


07/23/15
20150202275 
 Plague vaccine patent thumbnailPlague vaccine
The application relates to a yersinia pseudotuberculosis cell, which comprises nucleic acid coding for expression of at least one yersinia pestis caf1 polypeptide or of at least one antigenic fragment of yersinia pestis caf1, more particularly to an attenuated y. Pseudotuberculosis cell, which expresses the y.

07/23/15
20150202273 
 Prostate-specific tumor antigens and uses thereof patent thumbnailProstate-specific tumor antigens and uses thereof
Twenty-one psgr-derived peptides predicted by an immuno-informatics approach based on the hla-a2 binding motif were examined for their ability to induce peptide-specific t cell responses in peripheral blood mononuclear cells (pbmcs) obtained from either hla-a2+ healthy donors or hla-a2+ prostate cancer patients. The recognition of hla-a2 positive and psgr expressing lncap cells was also tested.

07/16/15
20150197389 
 Heat insulation cold closet for medical supplies patent thumbnailHeat insulation cold closet for medical supplies
The invention relates to a heat insulation cold closet for medical supplies, comprising a closet body with an opening, and a cover body sealed and meshed with the opening; the closet body, from inside to outside, successively consists of a rigid polyurethane layer, a vacuum heat insulation panel layer, a foamed polyurethane panel layer and a housing. The coefficient of heat insulation is smaller than or equal to 0.004 w/mk, heat radiation, heat conduction and heat convection between the interior of the closet body and the external environment can be effectively prevented, and the heat insulation closet can guarantee that the interior temperature is controlled at 2-8° c.
Suzhou Antekpac Industrial Co., Ltd.


07/16/15
20150196487 
 Vaccine formulations comprising saponin-containing adjuvants patent thumbnailVaccine formulations comprising saponin-containing adjuvants
The present invention provides for a novel oil-in-water (o/w) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof..
Merial Limited


07/09/15
20150191523 
 Toll-like receptors patent thumbnailToll-like receptors
The present invention relates to toll-like receptors, to cells comprising such toll-like receptors, to methods for the detection of immunostimulatory oligodeoxynucleotides wherein such methods use such toll-like receptors, to immunostimulatory oligodeoxynucleotides detected by use of this method, to the use of such immunostimulatory oligodeoxynucleotides in medicine and to vaccines comprising such immunostimulatory oligodeoxynucleotides.. .
Intervet International B.v.


07/09/15
20150191518 

Novel malaria transmission-blocking vaccines


Immunogenic compositions, vaccines, constructions, host cells, and vectors that include or express one or more pfgap50 antigen or fragment thereof. The vaccine may include an adjuvant, a pharmaceutically acceptable salt, an excipient, a preservative, a binder or a pharmaceutically acceptable liquid..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v


07/09/15
20150191516 

Ly6k epitope peptides for th1 cells and vaccines containing the same


Isolated ly6k-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


07/09/15
20150191514 

Hyr1-derived compositions and methods of treatment using same


The disclosure features isolated polypeptides of hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or acinetobacter infections or both.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center


07/09/15
20150190521 

Pneumococcal capsular saccharide conjugate vaccine


The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22f saccharide conjugate.
Glaxosmithkline Biologicals S.a.


07/09/15
20150190505 

Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator


The invention discloses a novel tumor-specific complete vaccine system generated in-vivo. This vaccine system is developed by the use of separated tumor cells inactivated by irradiation and the in-vivo interaction with an oncolytic viral vector with transgenic expression of gm-csf, completed with immune checkpoint modulators (“icm”) such as co-stimulatory signals confirmation with an anti-ctla4 antibody.

07/09/15
20150190502 

Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof


The present invention provides compositions or vaccines that contain a recombinant ehv-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant ehv-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.. .
Merial Limited


07/09/15
20150190495 

Arterivirus protein and expression mechanisms


The invention provides the discovery and characterization of a novel arterivirus protein (nsp2tf), whose expression is dependent on −2 ribosomal frameshifting at a site located in the nsp2 coding region. The coding region for the unique tf domain of nsp2tf overlaps the part of orf1a that encodes the transmembrane region of nsp2 in arteriviruses, including prrsv, ldv and shfv.
University College Cork


07/09/15
20150190493 

Combination vaccines with serogroup b meningococcus and d/t/p


Serogroup b meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“dtp”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type dtp ratios.
Novarits Ag


07/09/15
20150190492 

Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells


The invention is directed to bioconjugate vaccines comprising n-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having n-acetylgalactosamine at the reducing terminus.
Glycovaxyn Ag


07/09/15
20150190490 

Cdca1 epitope peptides for th1 cells and vaccines containing the same


Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


07/09/15
20150190489 

Kif20a epitope peptides for th1 cells and vaccines containing the same


Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science. Inc.


07/02/15
20150183857 

Methods and compositions comprising supramolecular constructs


The present invention comprises novel compositions and methods for eliciting high immune responses, of great specificity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, p170 glycoprotein.
Ac Immune Sa


07/02/15
20150182615 

Anti-bacterial vaccine compositions


Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.. .
Zoetis P&u Llc


07/02/15
20150182613 

Meningococcal and pneumococcal conjugate vaccine and using same


This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both s. Pneumoniae and n.
The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt


07/02/15
20150182610 

Live, oral vaccine for protection against shigella dysenteriae serotype 1


The invention relates to salmonella typhi ty21a comprising core-linked shigella dysenteriae serotype 1 o-specific polysaccharide (o-ps) and dna encoding o antigen biosynthesis, said dna selected from the group consisting of: a) the dna sequence set out in any one of seq id nos: 1 and 2 and species homologs thereof; b) dna encoding shigella dysenteriae serotype 1 polypeptides encoded by any one of seq id nos: 1 and 2, and species homologs thereof; and c) dna encoding a o antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the dna of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.. .
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services


07/02/15
20150182564 

Probiotic for amelioration of coccidiosis vaccine reaction


Methods for improving the health of agricultural poultry are provided. For example, methods including selecting specific bacteria to form a probiotic for the administration with coccidiosis vaccines for the reduction of adverse effects associated with the coccidiosis vaccines are disclosed.
Pacific Vet Group-usa, Inc.


07/02/15
20150182456 

Hydrogel vaccine formulations


This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. Beads, comprising a matrix material which matrix material comprises a microorganism.
Sigmoid Pharma Ltd.


06/25/15
20150175976 

Modified vaccinia virus strains for use in diagnostic and therapeutic methods


Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided.
Genelux Corporation


06/25/15
20150175670 

Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a


The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.


06/25/15
20150174234 

Influenza vaccines with reduced amount of emulsion adjuvant


Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses.
Novartis Vaccines And Diagnostics Srl


06/25/15
20150174233 

Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions


Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of m. Hyo infection, preferably m.
Boehringer Ingelheim Vetmedica, Inc.


06/25/15
20150174226 

Ompa and asp14 in vaccine compositions and as diagnostic targets


Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University


06/25/15
20150174223 

Ube2t peptides and vaccines containing the same


Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the ube2t that elicit ctls are provided.
Onco Therapy Science, Inc.


06/25/15
20150174208 

Cosmetic and pharmaceutical composition with modified olygopeptides in form of supramolecular assembly


The invention is a cosmetic and pharmaceutical liposomal composition which comprises a mixture of carboxylated oligopeptides derived from natural polypeptides; insulin; hyaluronidase and collagenase by their enzymatic hydrolysis; followed by a carboxylation of the free amino groups of lysine, histidine, and additional hydrolysis of terminal amino groups in the oligopeptides. Natural polypeptides may be hydrolyzed with a proteolytic enzyme to form a mixture of oligopeptides and succinylated them.

06/18/15
20150168402 

Novel immunogenic proteins of leptospira


The invention provides novel immunogenic proteins liga and ligb from leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.. .
Cornell University


06/18/15
20150168401 

Compositions and methods for immunodominant antigens of mycobacterium tuberculosis


Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen m. Tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests.
Immport Therapeutics, Inc.


06/18/15
20150166955 

Method for loading of dendritic cells with class i antigens


Disclosed is a method to obtain dendritic cells loaded with an exogenously added antigen. The method is in particular applicable to human cell lines that may be used in the production of dendritic cell vaccines, e.g.
Dcprime B.v.


06/18/15
20150166613 

Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a


The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.


06/18/15
20150166612 

Vaccines and methods for using the same


Improved anti-hcv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus hcv genotype 1a, including for example, ns4b, ns5a and ns5b.
Inovio Pharmaceuticals, Inc.


06/18/15
20150166610 

Recombinant rsv antigens


This disclosure provides recombinant respiratory syncytial virus (rsv) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of rsv infection.. .
Glaxosmithkline Biologicals, S.a.


06/18/15
20150165020 

Micromolded or 3-d printed pulsatile release vaccine formulations


Emulsion-based and micromolded (“mm”) or three dimensional printed (“3dp”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers.
Tokitae Llc


06/18/15
20150165019 

Saccharide conjugate vaccines


The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising t cell epitopes from two or more pathogens conjugated to saccharide antigen. The invention also provides a multivalent conjugate comprising two or more antigenically distinct saccharide antigens conjugated to the same carrier protein molecule, wherein the carrier protein comprises t cell epitopes from two or more pathogens.
Novartis Ag


06/18/15
20150165018 

Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals


The present invention is directed to a preferably live attenuated or subsequently inactivated african swine fever virus (asfv), comprising a non-functional genomic cd2 gene, wherein such asfv is non deficient in its replication, as well as to corresponding compositions or immunogenic compositions or vaccines, methods of production and uses for treating and/or preventing african swine fever in mammals, preferably of the family suidae, for instance pigs, more preferably domestic pigs (sus scrofa domesticus), wild pigs (sus scrofa scrofa), warthogs (potamochoerus porcus), bushpigs (potamochoerus larvatus), giant forest hogs (hylochoerus meinertzhageni) as well as feral pigs.. .
Consejo Superior De Investigaciones Cientificas, Csic


06/18/15
20150165015 

Use of alpha-toxin for treating and preventing staphylococcus infections


Vaccines comprising an s. Aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections.
Glaxosmithkline Biologicals S.a.


06/11/15
20150159136 

Methods for inducing migration by dendritic cells and an immune response


Compositions and methods of activating dendritic cells with lmp1 and lmp1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. Lmp1 or lmp1-cd40 chimeric protein may be used to activate and mature dendritic cells.
University Of Miami


06/11/15
20150158917 

Novel toxin in type a clostridium perfringens


The present disclosure relates to a novel toxin of type a c. Perfringens and immunogenic compositions and vaccines thereof.
University Of Guelph


06/11/15
20150157708 

Conjugates for the prevention or treatment of nicotine addiction


Wherein m, n, w, -(spacer)-, x* and y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction..

06/11/15
20150157704 

Newcastle disease virus vectored herpesvirus vaccines


The present invention encompasses recombinant newcastle disease virus-herpesvirus vaccines or compositions. The invention encompasses recombinant ndv vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens.
Merial Limited


06/11/15
20150157703 

Method of rapidly producing improved vaccines for animals


A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal..
Harrisvaccines, Inc.


06/11/15
20150157702 

Pneumococcal serotype 6d


Disclosed is a new and emerging serotype of streptococcus pneumoniae designated serotype 6d, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit→2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1-4) ribitol (5→phosphate.
The Uab Research Foundation


06/11/15
20150157698 

Production and application of protozoa cultures of histomonas meleagridis (h. meleagridis)


The invention discloses a method for producing a single bacterial strain culture of histomonas meleagridis (h. Meleagridis), the method being characterised by the following steps: (a) providing a xenic culture of h.
Veterinarmedizinische Universitat Wien


06/11/15
20150157533 

Pharmaceutical glass packaging assuring pharmaceutical sterility


A sterile glass pharmaceutical container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The sterile glass pharmaceutical container undergoes a strengthening process that produces compression at the surface and tension within the container wall.
Corning Incorporated


06/04/15
20150152174 

Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof


The present invention discloses crystal structure of staphylococcus aureus clumping factor a (clfa) in complex with fibrinogen (fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of clfa targeted vaccines and therapeutic agents (including monoclonal antibodies).
The Texas A & M University System


06/04/15
20150151135 

Transdermal delivery of dna vaccines using non-thermal plasma


Exemplary systems and methods of delivering dna vaccines are disclosed herein. An exemplary methodology of delivering dna vaccines includes providing a plasma generator for applying plasma to a treatment area for a sufficient period of time to open one or more pores.
Ep Technologies Llc


06/04/15
20150150965 

Adjuvant


The present invention is based on the identification of the adjuvant properties of inorganic (metal/metal oxide) nanoparticles. As such, the invention provides an adjuvant comprising, consisting or consisting essentially of inorganic nanoparticle.
The University Court Of The University Of Edinburg


06/04/15
20150150962 

Chicken astrovirus responsible for runting stunting syndrome


The present invention includes isolated astroviruses capable of reproducing the full runting stunting syndrome (rss) disease spectrum in poultry, including a chicken astrovirus isolated from the gut of chickens (ckastv-gut), a cell culture chicken astrovirus ckastv-p5, and a chicken astrovirus isolated after back passage in chicken (ckastv-p5-ckp5), and infected cell lines, cell culture supernatants, polynucleotide sequences, vectors, polypeptides, compositions, and vaccines thereof. The present invention also includes diagnostic methods based on such isolated viruses and infected cell lines, cell culture supernatants, polynucleotide sequences, vectors, and polypeptides thereof, and methods of protecting poultry, including chickens, against rss by the administration of such isolated viruses and infected cell lines, cell culture supernatants, polynucleotide sequences, vectors, polypeptides, compositions, and vaccines thereof..
University Of Georgia Research Foundation, Inc.


06/04/15
20150150959 

Bacterial biofilm matrix as a platform for protein delivery


Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins.
Children's Medical Center Corporation


06/04/15
20150150957 

Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same


Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including psa, psma, steap and psca antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens psa, psma, steap and psca, as well as genetic constructs/vectors and vaccines expressing the sequences.
Inovio Pharmaceuticals, Inc.


05/28/15
20150147784 

Reagents and methods for detecting influenza virus proteins


Two universally conserved sequences from influenza type a neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the n-terminus of the type a neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed.
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health


05/28/15
20150147356 

Antipyretics to enhance tolerability of vesicle-based vaccines


A method for immunising a human subject, wherein the subject receives (i) an immunogenic composition comprising bacterial vesicles and (ii) an antipyretic, and wherein the immunogenic composition and the antipyretic are administered to the subject within 24 hours of each other. Paracetamol significantly reduces fever rates without negatively affecting the immunogenicity either of a meningococcal vesicle vaccine or of concomitantly-administered antigens..

05/28/15
20150147348 

Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein


The present invention relates to the field of vaccines directed against viruses of the hiv family. More particularly, it relates to an immunogenic compound comprising a peptide of the following formula (i) nh2-[nt]y-p-w-n-x-s-x2-s-n-x3-x4-x-x6-x7-i-w-[ct]z-cooh (i) which is covalently linked to a carrier protein consisting of a crm197 protein.
Innaviravx


05/28/15
20150147346 

Replikin sequences and their antibodies for diagnostics, therapeutics, and vaccines against prion and neurodegenerative disorders including alzheimer's disease


The present invention provides methods of diagnosing, treating, and preventing prion and neurodegenerative disorders including vaccines against prion diseases and neurodegenerative disorders.. .

05/28/15
20150147329 

Influenza treatment and/or characterization, human-adapted ha polypeptides; vaccines


The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.. .
Massachusetts Institute Of Technology


05/28/15
20150143823 

System and solar powered thermal management and transport


A refrigeration system for vaccine storage and/or transportation includes an inner chassis. One or more vertical lift carriages are positioned in the inner chassis and can house a plurality of vaccines, pharmaceuticals, and/or other perishable items.
The Regents Of The University Of California


05/21/15
20150141498 

Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids


The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of rna and mrna. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but also leads to a considerable increase of the transfection efficiency of a nucleic acid.
Curevac Gmbh


05/21/15
20150140041 

Personalized cancer vaccines and adoptive immune cell therapies


Cancer antigens containing mutations in an expressed gene of cancer cells from a cancer patient are identified. Sequences from cancer cells obtained using a parallel sequencing platform are selected by comparing to the patient's normal genes or to normal genes from an hla-matched individual.
Persimmune, Inc.


05/21/15
20150140035 

Autologous biological cancer vaccine


The present disclosure relates to an autologous biological cancer vaccine and to a method for preparing the same. The vaccine of the present application is a biological vaccine obtained from overexpressed proteins in the serum of cancer patients, proteins to which have been added immunological adjuvants such as an attenuated virus dna and amino acids in order to cause an immune response, blocking tumor cells.
Universidad Manuela Beltran


05/21/15
20150140034 

Oil-based adjuvants


The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, tlr-3 agonists, glycolipids, and mpl-a or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.. .
Zoetis Llc


05/21/15
20150140033 

C. perfringens alpha toxoid vaccine


The present invention describes vaccines that comprise c. Perfringens type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of c.
Intervet Inc.


05/21/15
20150140027 

Antigens and vaccines directed against human enteroviruses


The instant invention provides materials and methods for producing immunologically active antigens derived from members of the picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection.
Sentinext Therapeutics Sdn Bhd


05/21/15
20150140026 

Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system


The present disclosure relates to surface proteins of moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines.
Arne Forsgren Ab


05/21/15
20150139939 

Cancer stem cell targeted cancer vaccines


Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers.
Stemline Therapeutics, Inc.


05/21/15
20150136132 

Nasal dry powder delivery system for vaccines and other treatment agents


A nasal delivery device can include air-receiving section that has a first passageway therethrough to allow air to pass through the air-receiving section, a powder-reservoir receiving section sized to receive a powder reservoir, and a powder-delivery section that has a second passageway therethrough to allow aerosolized powder from the powder reservoir to pass through the powder-delivery section. The first passageway can have a first end and a second end, with the first end being further from the powder-reservoir receiving section and the second end being at or near the powder-reservoir receiving area.
Creare, Incorporated


05/21/15
20150136030 

Selective embryonic structure targeting and substance delivery device


The present disclosure relates to a device for delivering substances to specific embryonic structures, including heart and blood vessels, within a developing avian egg. The disclosure also relates to methods of using the device to produce enhanced avian embryos.
Merial Limited


05/14/15
20150132844 

Dendritic cell compositions and methods


Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° c.-34° c. For a period of approximately 6 to 96 hours from the time they are isolated from a subject.

05/14/15
20150132398 

Vaccine formulation of mannose coated peptide particles


A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as plga combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen.

05/14/15
20150132341 

Fish vaccine


The present invention relates to novel compositions for medical use, particularly for use as vaccines. The present invention relies upon the dependence of the bacteria of the species alliivibrio wodanis (formerly vibrio wodanis) in the pathogenesis in the unrecognized, novel disease wodanosis (norwegian: odinose), as well as in the chronic disease stages of winter ulcer in a composition together with moritella viscosa (m.

05/14/15
20150132339 

Adjuvanted formulations of streptococcus pneumoniae antigens


The efficacy of s. Pneumoniae vaccines can be enhanced by adjuvanting s.

05/14/15
20150132337 

Combination gas vaccines and therapeutics


Compositions useful for reducing the risk of, preventing, and/or treating s. Pyogenes (gas) infections which comprise combinations of gas antigens, nucleic acid molecules encoding the antigens, or antibodies which specifically bind to the antigens..

05/14/15
20150132334 

Methods for displaying polypeptides and uses thereof


Provided herein are methods and compositions for displaying a polypeptide on a tubular structure and uses of such displayed polypeptides in the production of antibodies or vaccines.. .

05/14/15
20150132333 

Clostridium difficile toxin-based vaccine


The present invention relates to recombinant fragments of c. Difficile tcda and tcdb that may be used in the development of vaccines against c.

05/14/15
20150132332 

Anti-hiv vaccine constructed based on amino acid mutations in attenuated live eiav vaccine


Provided are antigenic polypeptides of hiv envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of equine infectious anemia virus, dna constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating hiv infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against hiv in organism..

05/14/15
20150132331 

Influenza vaccine constructs


vaccine compositions and methods of producing and using the same are provided, which compositions comprise a modified ha stem domain in a trimeric configuration.. .

05/14/15
20150132330 

Influenza virus vaccines and uses thereof


Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.. .

05/14/15
20150132302 

Vaccine and uses thereof


The present disclosure provides immunogenic compositions, such as vaccines, including dna vaccines, and uses thereof, e.g., to suppress or prevent an immune response and/or to treat or prevent an autoimmune disease.. .

05/14/15
20150132285 

Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells


The present invention provides a method of making a proteinase-engineered cancer vaccine for treating a cancer patient, especially for cancer patient at advanced/metastatic stage. The cancer vaccine comprises dead cancer cells with unbroken plasma membrane wherein the extracellular proteins and extracellular portion of membrane proteins are cleaved by proteinase digestion.



Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5099

5275

3 - 0 - 112